Immunogenicity of SARS-CoV-2 mRNA Vaccination in Immunocompromised Individuals
Author Information
Author(s): Chen Puran, Bergman Peter, Blennow Ola, Hansson Lotta, Mielke Stephan, Nowak Piotr, Gao Yu, Söderdahl Gunnar, Österborg Anders, Smith C.I.Edvard, Vesterbacka Jan, Wullimann David, Cuapio Angelica, Akber Mira, Bogdanovic Gordana, Muschiol Sandra, Åberg Mikael, Loré Karin, Chen Margaret Sällberg, Ljungman Per, Buggert Marcus, Aleman Soo, Ljunggren Hans-Gustaf
Primary Institution: Karolinska Institutet, Stockholm, Sweden
Hypothesis
How do immunocompromised individuals respond to SARS-CoV-2 mRNA vaccination over a two-year period?
Conclusion
The study highlights the importance of continuous SARS-CoV-2 vaccine booster doses in enhancing antibody responses in immunocompromised patients.
Supporting Evidence
- Participants showed improved antibody responses after additional vaccine doses.
- Immunosuppressive treatments negatively impacted vaccine responses.
- Longitudinal data provided insights into the effectiveness of booster doses.
- Responses varied significantly among different immunocompromised subgroups.
- Continuous monitoring is essential for understanding long-term immunity.
- Vaccination strategies should be personalized for immunocompromised individuals.
- Emerging variants affected neutralization capacity but T cell responses remained robust.
- Regular booster doses are crucial for maintaining adequate immunity.
Takeaway
This study shows that people with weak immune systems can still build up protection against COVID-19 with extra vaccine doses over time.
Methodology
The study followed 355 immunocompromised individuals from the COVAXID trial, assessing their antibody responses and T cell activity over two years after vaccination.
Potential Biases
Potential bias due to the reliance on self-reported infection history and the variability in immunoglobulin replacement therapy.
Limitations
The study relied on public health guidelines for vaccination schedules, which may not have been uniform across participants.
Participant Demographics
Participants included various immunocompromised groups, such as those with primary immunodeficiencies and those undergoing treatments like HSCT.
Statistical Information
P-Value
<0.001
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website